We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 99.02%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FPRX
101
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$787K 0.01%
19,247
– –
INFI
102
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$772K 0.01%
580,400
– –
BDSI
103
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$620K 0.01%
210,021
– –
FLGT icon
104
Fulgent Genetics
FLGT
$548M
$599K ﹤0.01%
125,000
– –
TARA icon
105
Protara Therapeutics
TARA
$228M
$597K ﹤0.01%
7,465
– –
NVIV
106
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$580K ﹤0.01%
21
– –
MTEM
107
DELISTED
Molecular Templates, Inc.
MTEM
$505K ﹤0.01%
+4,827
New +$417K
TTOO
108
DELISTED
T2 Biosystems, Inc
TTOO
$420K ﹤0.01%
+20
New +$371K
CCXI
109
DELISTED
ChemoCentryx, Inc.
CCXI
$364K ﹤0.01%
49,064
– –
TMBR
110
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$171K ﹤0.01%
40
– –
TENX icon
111
Tenax Therapeutics
TENX
$65.5M
$126K ﹤0.01%
11
+7
+175% +$104K
BGMSP
112
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$98K ﹤0.01%
13,253
– –
BTX.WS
113
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$4K ﹤0.01%
20,084
– –
CRBP icon
114
Corbus Pharmaceuticals
CRBP
$201M
– –
-4,338
Closed -$820K
MCRB icon
115
Seres Therapeutics
MCRB
$45.8M
– –
-6,250
Closed -$1.41M
PTN
116
Palatin Technologies
PTN
$17.2M
– –
-1,640
Closed -$882K
RARE icon
117
Ultragenyx Pharmaceutical
RARE
$2.55B
– –
-25,000
Closed -$1.55M
CMRX
118
DELISTED
Chimerix, Inc.
CMRX
– –
-115,216
Closed -$628K
ALDR
119
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-217,328
Closed -$2.49M
BIVV
120
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-8,249
Closed -$496K
JUNO
121
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-50,000
Closed -$1.5M
ZGNX
122
DELISTED
Zogenix, Inc.
ZGNX
– –
-185,290
Closed -$2.69M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2017 Portfolio in Review

As of Q3 2017, Julian Baker held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Julian Baker added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Julian Baker's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Julian Baker fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Julian Baker's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Julian Baker opened 9 new positions and closed 9 in Q3 2017.
  • Julian Baker's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.